Charter Oak Capital Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,447 shares of the company's stock after buying an additional 405 shares during the period. Charter Oak Capital Management LLC's holdings in Johnson & Johnson were worth $2,375,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the stock. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $35,000. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. TD Capital Management LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $48,000. Iron Horse Wealth Management LLC grew its stake in shares of Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company's stock worth $53,000 after acquiring an additional 159 shares in the last quarter. Finally, Cowa LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $58,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Get
Johnson & Johnson alerts:
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company's stock, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.35% of the company's stock.
Johnson & Johnson Trading Up 1.0 %
JNJ stock opened at $155.00 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a fifty day moving average price of $158.02 and a two-hundred day moving average price of $167.16. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The stock has a market cap of $403.66 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts' consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm had revenue of $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. During the same period in the previous year, the business posted $2.13 earnings per share. The company's revenue for the quarter was down 4.4% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.92%. Johnson & Johnson's dividend payout ratio (DPR) is 67.06%.
Analyst Ratings Changes
JNJ has been the subject of several research reports. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a "neutral" rating and a $164.00 price target for the company. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a research note on Friday, January 20th. Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a "strong-buy" rating for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $173.67.
About Johnson & Johnson
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
See Also
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
